European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>Bondalti has secured &gt;50% acceptance, effectively completing the deal; control is achieved and the original merger-arbitrage thesis has transitioned into a post-offer clean-up phase with minimal execution risk remaining.</li>
<li>Ercros at €3.405 implies a ~2.9% spread to €3.505; this reflects timing to a follow-on exclusion OPA, not deal uncertainty, with expected exit in late May–June 2026.</li>
<li>The residual trade offers low-teens annualised returns over 2–3 months; liquidity remains limited (~€1m daily), making this a smaller-scale, low-beta carry opportunity rather than a scalable arbitrage.</li>
</ul>


Bondalti has secured &gt;50% acceptance, effectively completing the deal; control is achieved and the original merger-arbitrage thesis has transitioned into a post-offer clean-up phase with minimal execution risk remaining.
Ercros at €3.405 implies a ~2.9% spread to €3.505; this reflects timing to a follow-on exclusion OPA, not deal uncertainty, with expected exit in late May–June 2026.
The residual trade offers low-teens annualised returns over 2–3 months; liquidity remains limited (~€1m daily), making this a smaller-scale, low-beta carry opportunity rather than a scalable arbitrage.


Bondalti/Ercros: Control Secured; Residual 3% Spread into Delisting

<ul>
<li>The acceptance period for Bondalti’s €3.505 cash offer for Ercros runs 12 February–13 March 2026 (CNMV notice dated 11 Feb 2026 ver-3), formally initiating the endgame of the transaction.</li>
<li>With shares trading at €3.46, the remaining gross spread is ~1.30%, implying a high-certainty, short-dated carry profile into expected settlement in late March.</li>
<li>We recommend tendering into the offer. Acceptance risk was effectively neutralised in December when the minimum threshold was reduced to &gt;50%; at this stage, the trade is timing-driven rather than outcome-driven.</li>
</ul>


The acceptance period for Bondalti’s €3.505 cash offer for Ercros runs 12 February–13 March 2026 (CNMV notice dated 11 Feb 2026 ver-3), formally initiating the endgame of the transaction.
With shares trading at €3.46, the remaining gross spread is ~1.30%, implying a high-certainty, short-dated carry profile into expected settlement in late March.
We recommend tendering into the offer. Acceptance risk was effectively neutralised in December when the minimum threshold was reduced to &gt;50%; at this stage, the trade is timing-driven rather than outcome-driven.


Bondalti / Ercros – Offer Live; Tender Recommended

<ul>
<li>Bondalti lowered the minimum acceptance threshold to &gt;50%, materially reducing execution risk and shifting the Ercros takeover into its final phase, with regulatory approvals complete and no interloper risk.</li>
<li>With Ercros closing at €3.42, the remaining spread to the €3.505 cash offer is ~2.5%, reflecting a market-implied completion probability near 90% and a high-confidence, short-dated carry profile.</li>
<li>Base-Case settlement: early to mid-February 2026 following CNMV approval and a standard acceptance period; returns are now driven by timing rather than outcome. Liquidity remains thin and sizing discipline essential.</li>
</ul>


Bondalti lowered the minimum acceptance threshold to &gt;50%, materially reducing execution risk and shifting the Ercros takeover into its final phase, with regulatory approvals complete and no interloper risk.
With Ercros closing at €3.42, the remaining spread to the €3.505 cash offer is ~2.5%, reflecting a market-implied completion probability near 90% and a high-confidence, short-dated carry profile.
Base-Case settlement: early to mid-February 2026 following CNMV approval and a standard acceptance period; returns are now driven by timing rather than outcome. Liquidity remains thin and sizing discipline essential.


Bondalti-Ercros: Acceptance Risk Removed, Deal Enters Final Execution Phase

<ul>
<li>Spain’s Ministry of Economy has validated the CNMC’s conditional approval of Bondalti’s €3.505/share bid, removing all regulatory risk and shifting the focus entirely to CNMV processing, acceptance, and deal execution.</li>
<li>Ercros’s deteriorating fundamentals and thin liquidity heighten shareholder-acceptance uncertainty; ~75% tender is required, while prior minority opposition and elevated trough-cycle multiples complicate the risk-reward despite regulatory de-risking.</li>
<li>With shares at €3.30, the spread has compressed to ~6%, offering a short-dated carry trade with a 45–55% annualised IRR if settlement occurs by February 2026, versus a €2.56 break.</li>
</ul>


Spain’s Ministry of Economy has validated the CNMC’s conditional approval of Bondalti’s €3.505/share bid, removing all regulatory risk and shifting the focus entirely to CNMV processing, acceptance, and deal execution.
Ercros’s deteriorating fundamentals and thin liquidity heighten shareholder-acceptance uncertainty; ~75% tender is required, while prior minority opposition and elevated trough-cycle multiples complicate the risk-reward despite regulatory de-risking.
With shares at €3.30, the spread has compressed to ~6%, offering a short-dated carry trade with a 45–55% annualised IRR if settlement occurs by February 2026, versus a €2.56 break.


Bondalti-Ercros: From Regulatory Clearance to Shareholder Countdown

<ul>
<li>CNMC approval with commitments de-risks the regulatory leg, shifting focus to shareholder acceptance and the Ministry’s decision; the spread has compressed but still offers short-dated, event-driven upside.</li>
<li>Ercros’s weak H1 performance and cyclical trough distort multiples; the €3.505 offer equates to ~9x EBITDA today but nearer 6× on normalized levels, consistent with control transaction benchmarks.</li>
<li>Base-Case IRR exceeds 100% annualized if settled by December; downside anchored by €2.56 break price, while any price bump toward €4.40 adds optionality without being part of the base case.</li>
</ul>


CNMC approval with commitments de-risks the regulatory leg, shifting focus to shareholder acceptance and the Ministry’s decision; the spread has compressed but still offers short-dated, event-driven upside.
Ercros’s weak H1 performance and cyclical trough distort multiples; the €3.505 offer equates to ~9x EBITDA today but nearer 6× on normalized levels, consistent with control transaction benchmarks.
Base-Case IRR exceeds 100% annualized if settled by December; downside anchored by €2.56 break price, while any price bump toward €4.40 adds optionality without being part of the base case.


Ercros: Regulatory Green Light, Shareholder Hurdles Ahead

Spain

Ercros SA is an industrial company focused on the manufacture and sale of chemical and pharmaceutical products. It is listed on the Spanish Stock Exchange.  The company is divided  into three areas of activity: a business strategic unit, the intermediate chemicals division, and the pharmaceuticals division. Ecros serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ercros (ECR SM)

Bondalti/Ercros: Control Secured; Residual 3% Spread into Delisting

Bondalti has secured control of Ercros, removing deal risk. Shares at €3.405 imply a ~2.9% spread to €3.505, offering low-teens IRR into a likely...

Jesus Rodriguez Aguilar

Bondalti / Ercros – Offer Live; Tender Recommended

Ercros tender period opens for Bondalti’s €3.505 offer. Shares at €3.46 imply ~1.3% gross carry into March settlement. Completion risk minimal;...

Jesus Rodriguez Aguilar

Bondalti-Ercros: Acceptance Risk Removed, Deal Enters Final Execution Phase

Bondalti has de-risked its Ercros bid by cutting the acceptance threshold to 50%. With shares at €3.42 versus a €3.505 offer, the trade is now a...

Jesus Rodriguez Aguilar

Bondalti-Ercros: From Regulatory Clearance to Shareholder Countdown

Bondalti’s bid for Ercros is fully cleared. Only shareholder acceptance remains. A 6% spread offers short-dated carry into early 2026, but...

Jesus Rodriguez Aguilar

Ercros: Regulatory Green Light, Shareholder Hurdles Ahead

CNMC clears Bondalti’s Ercros bid with remedies; focus shifts to acceptance and timing. Trough earnings inflate multiples, but >100% IRR keeps ECR...

Jesus Rodriguez Aguilar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)